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ABSTRACT
The potent ability of CRISPR/Cas9 system to inhibit the expression of targeted 
gene is being exploited as a new class of therapeutics for a variety of diseases. 
However, the efficient and safe delivery of CRISPR/Cas9 into specific cell populations 
is still the principal challenge in the clinical development of CRISPR/Cas9 therapeutics. 
In this study, a flexible aptamer-liposome-CRISPR/Cas9 chimera was designed to 
combine efficient delivery and increased flexibility. Our chimera incorporated an 
RNA aptamer that specifically binds prostate cancer cells expressing the prostate-
specific membrane antigen as a ligand. Cationic liposomes were linked to aptamers 
by the post-insertion method and were used to deliver therapeutic CRISPR/Cas9 
that target the survival gene, polo-like kinase 1, in tumor cells. We demonstrate 
that the aptamer-liposome-CRISPR/Cas9 chimeras had a significant cell-type binding 
specificity and a remarkable gene silencing effect in vitro. Furthermore, silencing 
promoted a conspicuous regression of prostate cancer in vivo. Importantly, the 
approach described here provides a universal means of cell type–specific CRISPR/
Cas9 delivery, which is a critical goal for the widespread therapeutic applicability of 
CRISPR/Cas9 or other nucleic acid drugs.
INTRODUCTION
Clustered regularly-interspaced short palindromic 
repeats (CRISPRs) is first identified in bacteria and 
archaea as an adaptive immune response via encoding 
CRISPR RNAs to guide CRISPR-associated (Cas) 
nucleases to invading genetic material [1, 2]. Later, the 
potential of Cas9 from the type II CRISPR system of S. 
pyogenes in RNA-guided precise genome editing is found 
in eukaryotic organisms [3–6], which is rapidly proving 
to be an efficient DNA-targeting strategy for multiple 
applications including gene expression modulation [7] and 
imaging [8]. Cas9 uses gRNA to locate site-specific DNA 
sequence, form base pairs and introduce a double strand 
break. Altering the first 20 nt of the gRNA can direct Cas9 
nuclease to specific sites, CRISPR/Cas9 therefore provides 
uniquely flexible and accessible means for genome 
editing. In view of its specificity, efficiency, simplicity and 
versatility, CRISPR/Cas9 system shows great promise for 
the treatment of many diseases, such as genetic disorders, 
cancer, and virus infection [9–11]. Like other biological 
drugs, CRISPR/Cas9-based therapeutics often require a 
delivery vehicle to transport them to the targeted tissues 
or cells. Thus, the advancement of numerous CRISPR/
Cas9 drugs has relied on the development of CRISPR/
Cas9 carriers [12]. However, the efficient in vivo delivery 
of CRISPR/Cas9 remains a major challenge, thus greatly 
restrains its clinic application [12]. Particularly, targeted 
delivery techniques for CRISPR/Cas9 into specific cell 
populations or tissues is highly desirable for improving the 
safety and efficacy of CRISPR/Cas9- based therapeutics.
The development of targeted delivery has 
progressed rapidly in recent years. Two indispensable 
parts are required for an ideal targeted delivery system: 
(i) a safe vehicle, which can protect RNA from nuclease 
degradation in the bloodstream; (ii) a targeting moiety/
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ligand, which can specifically recognize the receptor and 
effectively escort cargo into a selective tissue or cell. 
Thus, a targeting ligand with high specificity and affinity 
to a cellular receptor is a crucial factor in establishing a 
targeted CRISPR/Cas9 delivery system [13].
More recently, nucleic acid-based aptamers have 
been described as non-protein-based alternatives to 
antibodies, and thus possess the potential as targeting 
agents for the delivery of cargoes [14]. A new concept 
dubbed as ‘escort aptamers’ by Hicke and Stephens [15] 
develops a new field of aptamer functionality. The nucleic 
acid composition endows escort aptamers with unique 
features including high sensitivity and specificity, small 
size, low immunogenicity, and convenience of in vitro 
selection which enable escort aptamers applicable in 
various molecular targeting [16]. 
Quite a few aptamers have been successfully 
adapted for the targeted delivery of active therapeutics 
in vitro and in vivo via specific cell surface receptors. For 
example, cell-internalizing aptamers have been applied 
to specifically deliver siRNAs into target cells [17]. The 
best characterized and well-established aptamers for 
molecules delivery are the prostate-specific membrane 
antigen (PSMA) aptamers [18].  It has been reported that 
a gp120 aptamer-siRNA chimera successfully delivers 
siRNAs targeting the HIV-1 tat/rev common exon in 
both cell and mouse models [19, 20]. Additionally, 
aptamer-siRNA conjugates is able to deliver siRNAs into 
tumor cells [18, 21, 22]. However, the targeted delivery 
of CRISPR/Cas9 system has not been reported yet. In the 
present study, we intend to develop a universal system 
that combines efficient delivery and modified flexibility. 
An aptamer-liposome-CRISPR/Cas9 chimera-based 
approach is described for specific delivery of gRNA. 
The RNA aptamer A10 is reported to deliver therapeutic 
CRISPR/Cas9-gRNA targeting polo-like kinase 1, a 
pro-survival gene overexpressed in most human tumors 
into prostate cancer cells via specifically binding to the 
cell-surface receptor PSMA. We demonstrate that the 
aptamer-liposome- CRISPR/Cas9 chimeras not only had a 
significant cell-type specificity in binding and a remarkable 
gene silencing effect in vitro, but also a conspicuous 
tumor regression in vivo. Notably, the approach 
introduced here provides a means of cell type-specific 
CRISPR/Cas9 delivery to realize the therapeutic 
applicability of CRISPR/Cas9.
RESULTS
Preparation and characterization of A10-
liposome-siRNA chimeras
A10-liposome-CRISPR/Cas9 chimeras were 
prepared using a post-insertion method by mixing poly 
(ethylene glycol)-grafted 1,2-distearoyl-sn-glycero-
3-phosphatidylethanolamine (DSPE-PEG)-modified 
A10 and liposome- CRISPR/Cas9 complexes at room 
temperature. The liposome/gRNA ratio was 300:1, and 
the weight ratio of protamine/gRNA was 0.75. As shown 
in Figure 1, the liposome- CRISPR/Cas9 chimeras were 
of the appropriate particle size and zeta potential. The 
average particle size of A10-liposome- CRISPR/Cas9 
chimeras as determined by dynamic light scattering 
was ~150 nm (Figure 1A, left panel). Zeta potential 
is a key factor in the stability of a colloidal dispersion. 
Weak negative charges of ~40 mV were observed for 
the prepared chimeras (Figure 1A, right panel). TEM 
(Transmission Electron Microscope) (Figure 1B) verified 
the size and showed that the A10-liposome-siRNA 
chimeras consist of uniform particles.
Modified A10 binds PSMA-expressing cells
To determine the binding of the 
A10-liposome- CRISPR/Cas9 chimeras to PSMA on 
prostate cancer cells, we performed competition assays 
against PE-labeled PSMA antibody bound to LNCap 
cells. LNCap cells were selected because PSMA 
specifically existed on the surface of LNCap rather than 
PC-3 prostate cancer cell line [23] (Total PSMA protein 
expression in LNcap and PC-3 cells was determined 
by Western Blotting). As a control, staining with 
PE-labeled PSMA antibody was shown to be competed 
competitively by unlabeled PSMA antibody (Figure 2A). 
As an additional control, we tested binding of PE-labeled 
PSMA antibody on LNCap cells pretreated with the 
5-a-dihydrotestosterone (DHT) which could reduce 
the expression of PSMA. As expected, the binding of 
PE-labeled PSMA antibody was reduced following DHT 
treatment, verifying the correlation of binding to PSMA 
on the cells surface (Figure 2B). These results confirm the 
specificity and quantitative ability of this assay.
To assess the ability of the aptamer and modified 
aptamer conjugates to bind to PSMA on the surface 
of prostate cancer cells, PE-labeled PSMA antibody 
was bound to LNCap cells, and then the competition 
ability of the aptamer complexes was tested. These 
aptamer complexes included A10 without modification, 
DSPE-PEG linked A10, mut-A10 (a non-targeting 
A10 RNA sequence with two mutated bases) and 
A10-liposome-CRISPR/Cas9 chimeras. Bindings of both 
A10 (Figure 2C) and DSPE-PEG linked A10 (Figure 2D) 
showed significant competition relative to PE-labeled 
PSMA antibody, while mut-A10 (Figure 2E) was unable 
to compete with the PSMA antibody. This demonstrates 
that A10 aptamer with or without DSPE-PEG modification 
has the ability to specifically bind to PSMA on LNCap 
cells, and this binding is dependent on the sequence-
specificity of A10 RNA. Binding of DSPE-PEG linked 
A10 (Figure 2D) and A10-liposome- CRISPR/Cas9 
chimeras (Figure 2F) showed similar competition against 
binding of PE-labeled PSMA antibody, indicating that 
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Figure 1: Characterization of A10-liposome-CRISPR/Cas9 chimeras. (A) Size and Zeta potential of A10-liposome- CRISPR/
Cas9 chimeras. The liposome-CRISPR/Cas9 chimeras were determined using a Nano Zetasizer (Malvern Instrument Ltd.) in HEPES 
buffer. (B) Transmission electron photomicrograms of cationic liposomes. Particles were imaged using an accelerating voltage of 80 kV 
(magnification: × 60, 000).
Figure 2: Cell surface competition assay of modified A10 binding to PSMA. PE-labeled PSMA antibody was bound to 
LNCap cells (red), and then competition assays were performed with unlabeled PSMA antibody as a positive control (A) or with different 
modified A10 conjugations (antibody competitors) (C–F) (blue). Cell surface competition was assessed by flow cytometry. As a control 
for specificity of binding, DHT treatment, which is known to reduce total PSMA protein expression, was shown to reduce the binding 
of PE-labeled PSMA antibody (B). Total PSMA protein expression in LNcap or PC-3 cells was determined by Western Blotting. The 
percentage of PE positive cells following the addition of each competitor is listed in the table.
Oncotarget9378www.impactjournals.com/oncotarget
aptamer-containing chimeras retain their ability of binding 
PSMA on the surface of LNCap cells. 
Assessment of liposome- CRISPR/Cas9 chimera 
activity by in vitro gene knockdown assay
To demonstrate the biological activity of 
liposome-CRISPR/Cas9 chimeras, we analyzed PLK1 
mRNA levels by RT-PCR in cells after treatment 
with different formulations of CRISPR/Cas9 reagents 
(Figure 3). Free PLK1 CRISPR/Cas9 (Figure 3A, 
lane 2) had little effect due to the poor cellular 
bioavailability of its negative charge. Liposome chimeras 
containing protamine and calf thymus DNA (Figure 3A, 
lane 5, 7) down-regulated PLK1 mRNA, better than the 
corresponding result of liposome- CRISPR/Cas9 chimeras 
without protamine and calf thymus DNA (Figure 3A, 
lane 4, 6), suggesting that protamine and calf thymus 
can partly improve the transfection efficiency. It also can 
be seen that, even without A10, the liposome-CRISPR/
Cas9 chimeras (Figure 3A, lane 5) we described had the 
same effect of lipofectamine-2000 (Figure 3A, lane 3), an 
acknowledged commercial transfection reagent. Further, 
with the attendance of A10, the liposome-CRISPR/Cas9 
chimeras (Figure 3A, lane 7) down-regulated 63% PLK1 
mRNA, significantly better than chimeras without A10 
(Figure 3A, lane 5) (P < 0.01). In contract to LNCap 
cells, PLK1 mRNA knockdown in PC-3 cells had no 
correlations with chimeras’ formulation, only depended 
on CRISPR/Cas9 targeting (Figure 3B). These results 
demonstrate that A10 aptamer greatly improves the 
transfection efficiency.
To verify that silencing effect of liposome-CRISPR/
Cas9 chimeras was dependent on PSMA,  LNcap 
cells were incubated with 2 nM DHT for 48 h before 
the addition of chimeras (Figure 3A, lane 8, 9). In the 
presence of DHT, PLK1 gene silencing was significantly 
less effective (Figure 3A, lane 6, 7). In PC-3 cells, there 
was no difference before (Figure 3B, lane 6, 7, 11) and 
after DHT addition (Figure 3B, lane 12, 13, 14). These 
data indicate that the gene silencing effect of this novel 
delivery system is dependent on cell surface expression 
status of PSMA.
Assessment of liposome-CRISPR/Cas9 chimera 
activity in the intracellular uptake of CRISPR/
Cas9 in vitro
To verify that the increased gene silencing mediated 
by the A10-liposome- CRISPR/Cas9 chimeras and 
protamine + calf thymus DNA was due to increased 
delivery, we performed cellular uptake assays. The 
Figure 3: mRNA silencing in LNCap cells treated with different liposome chimeras. LNCap cells (A) or PC-3 cells 
(B) were transfected with 400 nM free CRISPR/Cas9 (panel 2), CRISPR/Cas9 transfected with Lipofectamine-2000 (panel 3, as positive 
control), liposome-CRISPR/Cas9 chimeras (panel 4), liposome-CRISPR/Cas9 chimeras with protamine and calf thymus (panel 5), 
A10-liposome-CRISPR/Cas9 chimeras (panel 6), A10-liposome-CRISPR/Cas9 chimeras with protamine and calf thymus (panel 7). 
As contrast, the silencing effect was also determined by scrambled CRISPR/Cas9 alone (panel 8), or formulated in Lipofectamine-2000 
(panel 9), or in liposome-chimeras with protamine and calf thymus (panel 10), or in A10-liposome chimeras (panel 11). PLK1 mRNA 
expression was assessed by RT-PCR. To further verify that silencing by liposome-CRISPR/Cas9 chimeras is dependent on PSMA, LNcap or 
PC-3 cells were incubated with 2 nM DHT for 48 h before the addition of chimeras. Then, cells were treated with A10-liposome- CRISPR/Cas9 
chimeras (panel 12), or A10-liposome-CRISPR/Cas9 chimeras with protamine and calf thymus (panel 13), or A10-liposome- scrambled 
CRISPR/Cas9 chimeras with protamine and calf thymus (panel 14). Results represent the mean + SD of PLK1 mRNA expression for 3 
replicates standardized to GAPDH mRNA expression and normalized to an average of 100% in the untreated cells. 2000, lipofectamine 
2000; P&C, protamine and calf thymus;  Lipo, liposome;  S, scramble gRNA *p < 0.05; **p < 0.01.
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uptake of fluorescently labeled CRISPR/Cas9 in the 
cytoplasm of cells was observed by confocal microscopy. 
As shown in Figure 4A, the uptake of CRISPR/Cas9 
formulated with liposome chimeras with protamine and 
calf thymus DNA (Figure 4E) was much greater than with 
liposome (Figure 4D) or lipofectamine-2000 (Figure 4C). 
Furthermore, the fluorescence signal in cells treated with 
A10-liposome-CRISPR/Cas9 chimeras (Figure 4F) was 
much stronger than that of cells treated with liposome 
alone (Figure 4E). Thus, these results indicated that 
liposome chimeras with A10 aptamer mediated the 
strongest gene silencing effect due to efficient delivery of 
CRISPR/Cas9 into LNCap cells. 
PLK1 was a valid target in tumors since its 
inhibition induced apoptosis in proliferating cancer 
cells [24, 25]. We then examined whether the indicated 
liposome chimeras either alone or in the presence of 
CRISPR/Cas9 could induce apoptosis in treated cells, and 
whether modifications of the liposomes could enhance 
their pro-apoptotic activity. As shown in Figure 4B, the 
apoptosis was originated from the downregulation of 
PLK-1 in LNCap cells.
Assessment of cell viability following treatment 
with liposome- CRISPR/Cas9 chimeras
PLK1 is a survival gene that is over-expressed in 
most human tumors [24, 25]. Therefore, knockdown 
PLK1 would be expected to reduce the viability of LNCap 
cells. To assess the cell viability following treatment 
with liposome chimeras, either alone or in the presence 
of CRISPR/Cas9, the cytotoxic effects of different 
liposome formulations were measured by MTT assay 
(Figure 5). Free CRISPR/Cas9 alone had low toxicity, 
consistent with its poor ability to knockdown genes 
without a delivery agent (Figure 3). In the absence of 
CRISPR/Cas9, our liposome chimera preparations (with 
or without A10 aptamer) were less toxic than commercial 
lipofectamine-2000, though the toxicity was increased 
somewhat with the addition of protamine and calf thymus 
Figure 4: Intracellular uptake of 5’-FAM labeled CRISPR/Cas9 in LNCap cells and analysis of cell apoptosis after 
treatment with in different liposome chimeras. (A) Cells were treated with different liposome-CRISPR/Cas9 formulations at 
37°C for 4 h. Cells were rinsed, fixed, and intracellular uptake of the CRISPR/Cas9 was imaged fluorescent microscopy. (A) no CRISPR/
Cas9; (B) gRNA empty vector-CRISPR/Cas9; (C) Lipofectamine-2000 + CRISPR/Cas9; (D) Liposome + CRISPR/Cas9; (E) Liposome 
+ Protamine + calf thymus DNA + CRISPR/Cas9; (F) A10-Liposome + Protamine + calf thymus DNA + CRISPR/Cas9. Magnification = 
400×. (B) Cell apoptosis following exposure to liposome chimeras.
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DNA. In the presence of scrambled CRISPR/Cas9, 
different formulation groups showed comparative toxicity 
to the lipofectamine-2000. These results suggest that the 
liposomes we developed are not inherently cytotoxic. 
However, the addition of CRISPR/Cas9 targeted 
PLK1 decreased the cell survival when added with 
lipofectamine-2000 or liposome, and this effect was 
greater when protamine and calf thymus DNA was added. 
The most dramatic decrease in viability was observed for 
the CRISPR/Cas9 delivered by A10-liposome chimeras 
with protamine and calf thymus DNA. Thus, the toxicity 
of the A10-liposome-CRISPR/Cas9 chimeras appears to 
be specific for the PLK1 CRISPR/Cas9 and correlates with 
differences in the specific uptake by the different delivery 
systems.
A10-liposome-CRISPR/Cas9 chimeras promote 
tumor regression
To determine the efficacy of A10-liposome-
CRISPR/Cas9 chimeras in vivo, we detected the ability 
of the A10-liposome-CRISPR/Cas9 chimeras to retard 
xenograft tumor growth in athymic mice derived from 
PSMA-positive human prostate cancer cells (LNCap). 
Mice bearing xenograft tumors larger than 0.2 cm3 were 
injected i.v. (day 0) with PBS, PLK1- CRISPR/Cas9 alone 
(free CRISPR/Cas9) or chimeric PLK1-CRISPR/Cas9 
(A10-liposome-scrambled CRISPR/Cas9, liposome- 
CRISPR/Cas9, or A10-liposome-CRISPR/Cas9). Tumors 
were measured every other day (Figure 6A). No obvious 
difference in tumor volume was observed between the 
PBS control and the free CRISPR/Cas9 group, showing 
that CRISPR/Cas9 delivery is necessary for tumor 
regression. Additionally, the A10-liposome-scrambled 
CRISPR/Cas9 group did not reduce tumor volume, 
suggesting specificity for the PLK1 CRISPR/Cas9 target 
sequence. In contrast, a substantial reduction in tumor 
volume was observed for both the liposome-CRISPR/Cas9 
group and the A10-liposome-CRISPR/Cas9 group. Indeed, 
from day 13 to day 27 the PBS-treated tumors 
increased 2.56-fold in volume, whereas the 
A10-liposome-CRISPR/Cas9 treated tumors reduced 1.66-
fold in volume. Compared to the liposome-CRISPR/Cas9 
group, the A10-liposome-CRISPR/Cas9 chimeras had 
a more significant regression (0.40 cm3 to 0.15 cm3), 
demonstrating that the regression of tumor volume is 
improved by the presence of A10. The Chi-square values of 
the survival rate of the A10-liposome-scramble CRISPR/
Cas9 group, liposome-CRISPR/Cas9 group and A10-
liposome- CRISPR/Cas9 group were 1.20, 6.00 and 11.58, 
respectively, only the latter two groups fell within the 99% 
confidence intervals for statistically significant difference 
Figure 5: Viability (%) of LNCap cells treated with different liposome chimeras. Cells were seeded at 105 cells/mL in a 
96-well plate and incubated at 37°C. Percentage of cell viability was determined following 24 h exposed to different liposome chimeras 
by MTT assay. data represents the percentage of cell viability compared with untreated cells. Data = mean ± SD (n = 6). * indicates a 
significant difference between two groups (p < 0.05).
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with free CRISPR/Cas9 group, suggesting liposome-
CRISPR/Cas9 group and A10-liposome- CRISPR/Cas9 
group displayed slightly stronger antitumor effect than 
the PBS group or free CRISPR/Cas9 group. Notably, 
no mortality was observed after 27-d treatment with the 
A10-liposome-CRISPR/Cas9 chimera, and no significant 
change in mouse body weight (Figure 6C ) was observed 
compared to that of control, suggesting that this compound 
was  non-toxic to the animals under the present conditions 
(Figure 6B, 6C). 
To further examine the effects of the A10-liposome-
CRISPR/Cas9 chimeras in vivo, As shown in (Figure 6D), 
xenografts derived from A10-liposome-PLK1 CRISPR/Cas9 
chimeras grew more slowly in comparison with PBS, free 
CRISPR/Cas9, or A10-liposome-scrambled CRISPR/Cas9 
chimeras. Histological examination of the tumor sections 
was performed. The tumor cells from mice treated with 
A10-liposome-PLK1 CRISPR/Cas9 chimeras, in contrast 
to those from mice treated with PBS, free CRISPR/Cas9, 
or A10-liposome-scrambled CRISPR/Cas9 chimeras, were 
vacuolated , extensively granulated, and showed evidence of 
necrosis (Figure 6F). Moreover, less epithelium was present 
in tumors from the A10-liposome- CRISPR/Cas9 chimera-
treated mice. Conversely, the control tumors were dense 
and composed primarily of epithelium. Occasional pockets 
of necrosis were exhibited in the A10-liposome-scrambled 
CRISPR/Cas9 chimera-treated tumors, indicating that non-
specific uptake and subsequent processing of the chimera 
might have occurred to a limited extent. However, because 
no substantial change in tumor volume was noted in the 
A10-liposome-scrambled CRISPR/Cas9 chimeras treated 
tumors (Figure 6A), we presumed that this uptake was an 
inefficient process.
In vivo immunostimulatory effects of liposome- 
CRISPR/Cas9 chimeras
The potential immunostimulatory effects of 
the liposome-CRISPR/Cas9 chimera delivery system 
were determined by assessing levels of IFN-a and 
IL-12 in mouse serum by ELISA. As shown in 
Figure 6E, CRISPR/Cas9 alone or formulated with 
targeting liposomes induced a very mild production of 
inflammatory cytokines in athymic nude mice. Compared 
to the poly (I:C) positive control, all formulations had no 
significant immunogenicity. Furthermore, the addition 
Figure 6: Antitumor activity of A10-liposome-CRISPR/Cas9 chimeras in a xenograft model of prostate cancer (n = 8 
/group). (A) Different CRISPR/Cas9 formulations (Free CRISPR/Cas9, red; liposomes-CRISPR/Cas9 chimera, green; A10-liposome-
scrambled CRISPR/Cas9 chimera, dark blue; A10-liposome-CRISPR/Cas9 chimera, light blue) were administered i.v. in a mouse xenograft 
model bearing PSMA-positive LNCap prostate cancer cells implanted into the shoulder flanks of nude mice. Saline (PBS) treated animals 
were used as a control (black). Tumors were measured every two days. The mean tumor volumes were analyzed using one-way ANOVA. 
*p < 0.05 vs the free CRISPR/Cas9 group. (B) Death protection for mice after treatment with different CRISPR/Cas9 formulations. The 
extension of death was analyzed using a sequential chi-square test. (C) Mice after treatment with different CRISPR/Cas9 formulations, 
body weight changes (D) Mice were sacrificed and the tumors were isolated. (E) Assessment of potential immunostimulatory effects 
promoted by the delivery system. Serum from mice treated with saline (PBS), free CRISPR/Cas9, A10-liposome-scrambled CRISPR/
Cas9, liposome-CRISPR/Cas9, A10-liposome-CRISPR/Cas9 or poly I:C was assessed for levels of IFN-α and IL-12 using ELISA. Data 
represent means ± SD (n = 5) (F) Histology of LNCap tumors treated with the various chimeras. Serial sections of formalin-fixed tumors 
embedded in paraffin were stained with hematoxylin and eosin (H&E) and analyzed at 5× and 40× magnification (boxed region is amplified 
eight times in the bottom panels).
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of A10 to the targeting formulation induced lower levels 
of cytokines than the liposome CRISPR/Cas9 alone 
verifying that A10 conjugation reduces non-specific 
immunostimulatory effects, likely due to its ability to 
increase cell specificity.
DISCUSSION
Targeting tumors is an attractive application of 
CRISPR/Cas9 system. Although various methods have 
been described for delivering CRISPR/Cas9, few reports 
have accomplished therapeutic success. One possible 
reason for the lack of success in in vivo studies is the 
nonspecific delivery effects. Therefore, cell type-specific 
delivery of gRNAs is a critical goal for the widespread 
applicability of this therapeutic technique due to both 
safety and cost considerations. a system which combines 
the efficient delivery and modified flexibility is likely 
to become the next focus of targeted delivery systems. 
Three considerations are important for developing this 
approach: the CRISPR/Cas9 designed to knockdown genes 
in a defined population of cells; the targeting moiety that 
specifically recognizes surface receptors expressed on the 
cell population of interest; and a low immunostimulatory 
system that links CRISPR/Cas9 to the targeting moiety with 
low cost, high ease and flexibility, optional modification, 
and suitable safety. Toward this end, using human prostate 
cancer as an example, we developed an aptamer-liposome 
based CRISPR/Cas9 chimera that recognized the PSMA 
receptor expressed on many prostate cancer cells.
For many potential therapeutic applications of 
chimeras that require systematic administration of 
therapeutic reagent, optimization of the formulation 
is necessary for full potential. The RNA aptamer A10 
has been reported to have the capability to bind PSMA 
[26, 27], and therefore, our chimeras were designed with 
this RNA aptamer. This aptamer was modified with 2’-F 
and 3’-NH2 during the process of transcription to improve 
its stability and provide a convenient linkage21. Moreover, 
because terminal modification of RNAs with PEG 
increases the half-life of many oligonucleotide-based 
therapies, including RNA aptamers [28], PEGylation 
was also introduced into the chimera. Our results 
demonstrate that the binding of A10 is more competitive 
when modified with DSPE-PEG2000 (Figure 2D) than 
the A10 aptamer (Figure 2C).  This suggests that 
appropriate modification can promote the function of 
aptamers without affecting chimera targeting (Figure 2) 
or knockdown (Figure 3). 
The in vitro cell surface binding of different 
formulations demonstrated that cellular targeting of the 
chimeras was mediated by the interaction of the aptamer 
portion of the novel delivery system with PSMA on 
the cell surface (Figure 2B; Figure 3, lanes 8 and 9). 
The gene knockdown effect of different formulations 
showed high correlation with the CRISPR/Cas9-gRNA 
sequence and the intracellular delivery efficiency 
(Figure 3). Notably, in the presence of A10, liposome-
CRISPR/Cas9 chimeras provided much greater delivery 
efficiency and higher gene knockdown activity than 
other formulations, demonstrating that the function of 
the delivery system was dependent on the interaction of 
A10 and PSMA. 
Because many potential therapeutic applications 
of chimeras, including cancer therapy, require systemic 
administration of the therapeutic reagent, it is also 
necessary to optimize potency and specificity in vivo. 
The in vivo activity of the A10-liposome-CRISPR/
Cas9 chimeras in promoting tumor regression was 
consistent with the in vitro observations, in which 
the A10-liposome- CRISPR/Cas9 chimeras showed 
significantly higher activity than other formulations 
(Figure 6A). We believe the enhanced activity of 
this novel delivery system is mainly due to the 
significantly improved tumor uptake (Figure 4F) 
and the specific binding to LNCap cells (Figure 2F). 
Formulations including free CRISPR/Cas9, non-targeted 
liposome-CRISPR/Cas9 chimeras and scrambled 
CRISPR/Cas9 in A10-liposome chimeras had little effect 
(Figure 6A), while A10-liposome-PLK1 CRISPR/Cas9 
resulted in pronounced regression of tumors expressing 
PSMA in athymic mice after i.v. injection. The results 
suggest that significant gene knockingdown activity is 
highly dependent on the correct gRNA sequence and 
sufficient tumor delivery. Therefore, this delivery system 
is suitable for targeting tumors in vivo and could possibly 
be useful for therapeutic treatment of human prostate 
cancer in the future.
Previous studies have demonstrated a cytokine 
induction effect that is dependent on the CRISPR/Cas9 
and the formulation [29, 30]. Our results (Figure 6E) 
showed little immune response of nude mice with different 
CRISPR/Cas9 formulations. Compared to the positive 
control, CRISPR/Cas9 alone or with all formulations 
had no significant immunogenicity, suggesting that the 
formulations we developed are safer than other cationic 
liposome. We also found that the targeted CRISPR/Cas9 
delivery system, when formulated with A10, shows a 
lower immune response than non-targeted liposomes, 
which suggested that modification with A10 RNA aptamer 
has a potential ability to reduce the immunogenicity of the 
cationic liposome.
In principle, the current aptamer-liposome-CRISPR/
Cas9 chimera approach can be applied to the development 
of reagents targeting many different cell types, provided 
that a cell-type-specific receptor exists and that an aptamer 
against the receptor can be selected. The flexibility of 
modification on the targeting moiety or liposome also 
should enable this system to develop CRISPR/Cas9-based 




PC (prostate cancer) cell lines were obtained from 
American Type Culture Collection. LNCap cells (ATCC 
No. CRL-1740), PC-3 cells (ATCC No. CRL-1435) were 
grown in Roswell Park Memorial Institute medium 1640 
(RPMI 1640, Invitrogen) supplemented with 10% FBS, 
100 U/mL penicillin, and 100 U/mL streptomycin and 
were maintained at 37°C and 5% CO2. LNCap cells were 
shown to be PSMA positive by Western blotting [31] 
(Figure 2).
Materials
DOTAP, cholesterol, and DSPE-PEG2000 were 
purchased from Avanti Polar Lipid, Inc. unless otherwise 
noted, all chemicals were purchased from Sigma-Aldrich, 
all cell culture products were purchased from Gibco 
BRL/Life Technologies, a division of Invitrogen, and all 
restriction enzymes were obtained from New England 
BioLabs (NEB). 
Design and cloning of PLK1-specific gRNA
gRNA expression plasmids were constructed 
according to manufacturer’s protocol [32, 33] and detailed 
BLAST searches of the human and murine genomes were 
conducted to identify potential off-target binding of PLK1 
gRNAs. To assess the utility of PLK1-targeting gRNAs, 
oligonucleotide were designed to target the complete 
genomic PLK1 (5’-CGGAGGCTCTGCTCGGATCG-3’). 
All oligonucleotides were synthesized and purified by 
Sangon Biotech Co (Shanghai, China). Briefly, to prepare 
a 100-bp double-stranded DNA insert fragment containing 
the target sequence (20 bp) and a protospacer-adjacent 
motif sequence, we used a set of oligonucleotides and 
generated the fragment using T4 PNK (NEB, Ipswich, 
MA, USA). The double-stranded DNA fragment was 
purified and inserted into the BbsI site of a gRNA cloning 
vector with T4 DNA ligase (NEB).
Preparation of A10-liposome- CRISPR/Cas9 
chimeras
In vitro transcription of the A10 aptamer
Transcription was performed either with or without 
modified NTPs (2’F-dCTP, 2’F-dUTP and 3’NH2-
dUTP) according to the instructions of the DuraScribe® 
T7 Transcription Kit (Epicentre Biotechnologies). The 
20 μL transcription reactions contained 2 μL 10 × T7 
reaction buffer, 1 μL 100 mM ATP, 1 μL 100 mM GTP, 
2 μL 50 mM 2’F-dCTP or CTP, 2 μL 50 mM 2’F-dUTP or 
3’NH2-dUTP or UTP, 2 μL 100 mM DTT, 2 μL DuraScribe 




 and modified aptamer
Fifty microliters of DSPE-PEG2000-COOH (10 
μg/μL in DNase/RNase-free water) was incubated with 
100 μL of 800 mmol/L 1-(3-dimethylaminopropyl)- 
3-ethylcarbodimide hydrochloride (EDC) and 100 μL 
of 200 mmol/L N-hydroxysuccinimide (NHS) for 15 
min at room temperature with gentle stirring. Where 
indicated, the resulting NHS-activated DSPE-PEG2000 
was covalently linked to 50 μL of 3’-NH2–modified A10 
PSMA aptamer (1 μg/μL in DNase/RNase-free water). 
The aptamer-DSPE-PEG2000 bioconjugates were washed, 
resuspended, and preserved in suspension form in DNase/
RNase-free water.
Preparation of liposome-CRISPR/Cas9 chimeras
DOTAP and cholesterol were dissolved at a 3:1 
molar ratio in a mixture of chloroform in a glass vial. The 
solvent was removed by reverse evaporation in a rotary 
evaporator at 25°C, 0.06 MPa. Five milliliters of sterile 
deionized water was added to the dried lipid film, and the 
mixture was allowed to swell overnight. The lipids were 
then sonicated in a bath-type sonicator for 5 min followed 
by extrusion through 450 and 220 nm membrane filters 
5 times. This preparation was stored at 4°C before use. 
Novel liposome-CRISPR/Cas9 chimeras were composed 
of DOTAP/cholesterol liposome, protamine, and a 
mixture of gRNA and calf thymus DNA (0.75:1 weight 
ratio). To prepare the liposome-CRISPR/Cas9 chimeras, 
protamine (2 mg/mL), deionized water, and the gRNA/
calf thymus DNA mixture (2 mg/mL) were combined in a 
1.5 mL tube. The complex was allowed to stand at room 
temperature for 10 min before the addition of DOTAP/
cholesterol liposome (300:1 molar ratio vs gRNA). The 
liposome- CRISPR/Cas9 chimeras were incubated at room 





The resultant mixture of DSPE-PEG2000-A10 
bioconjugates (0.3:1 mole ratio vs DOTAP) and the 
liposome-CRISPR/Cas9 chimeras were incubated at 60°C 
for 1 h so that the ligand-anchors could rapidly insert into 
the outer liposome monolayer.
Characterization of the A10-liposome-CRISPR/
Cas9 chimeras
The particle size and zeta potential of the 
liposome-CRISPR/Cas9 chimeras were measured using 
the Nano Zetasizer (Malvern Instrument Ltd.). Average 
values were reported as the mean ± standard deviation. 
The liposome-gRNA chimeras were observed under 
transmission electron microscopy (TEM). Briefly, the 
liposomes were diluted ten-fold with distilled water 
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and applied to 300 mesh, formvarcarbon-coated Cu 
grids. Chimeras were then negatively stained with 
2% uranyl acetate (pH 4.8) for 30 s. Stained samples 
were characterized on a Philips CM120 TEM at a final 
magnification of 120,000 ×. Three grids were prepared for 
each sample and the grid openings were randomly selected 
and viewed.
Cell-surface binding competition assays
LNCaP or PC-3 cells were used for cell-surface 
binding competitive experiments. Anti-PSMA 3C6 
antibody (2 μg, R&D Systems Inc.), A10 aptamer, 
DSPE-PEG2000-A10, Mut-A10 aptamer or A10-
liposome-CRISPR/Cas9 chimeras were used as antibody 
competitors. Cells were trypsinized, washed twice 
with 500 mL PBS, and fixed in 400 mL of FIX solution 
(PBS + 1% formaldehyde) for 20 min at 25°C. After 
washing with PBS, cells pellets were re-suspended in 
1 × binding buffer (20 mM HEPES pH 7.4, 150 mM Nacl, 
2 mM CaCl2, 0.01% BSA) containing 2 μg (1 μg/μL) PE 
modified anti-PSMA 3C6 antibody at 37°C for 20 min. 
Then different competitors were added to compete with PE 
modified anti-PSMA 3C6 antibody in PBS with 4% FBS 
pre-warmed at 37°C for 20 min. Cells were washed three 
times with PBS, fixed in 400 μL of FIX, and analyzed by 
flow cytometry. 
In the 5-α-dihydrotestosterone (DHT, Sigma) 
treatment experiment, LNCap or PC-3 cells were grown 
in RPMI 1640 medium containing 5% charcoal-stripped 
serum for 24 h before the addition of DHT in RPMI 
1640 medium containing 5% charcoal-stripped FBS 
for 48 h. And then competition assays were performed 
with different competitors described above. Cell surface 
competition was assessed by flow cytometry.
Total PSMA expression was analyzed by western 
blotting. Cells were trypsinized, and counted using 
a hemocytometer. Cell pellets were re-suspended in 
1 × RIPA buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 
1 mM EDTA, 1 % NP-40) containing 1 × protease and 
phosphatase inhibitor cocktails (Sigma) and incubated on 
ice for 20 min. Split products were boiled with 2 × protein 
loading buffer, and 15 μL of total protein from the 
supernatants were resolved on a 12.5 % SDS-PAGE gel. 
PSMA was detected using a 1:1000 dilution of an antibody 
specific to human PSMA (Abnova) and a 1:2000 dilution 
of secondary antibody (goat anti-mouse IgG) in blocking 
buffer. b-actin was detected using a 1:1000 dilution of 
an antibody specific to human β-actin (Cell Signaling 
Technology, Inc.) and a 1:2000 dilution of secondary 
antibody (goat anti-mouse IgG) in blocking buffer.
Gene knockdown assay
LNCap or PC-3 cells were seeded in 6-well plates at 
60% confluency. Cells were transfected with CRISPR/Cas9 
on day 3 using Lipofectamine-2000 (Invitrogen) following 
the manufacturer’s recommendations. In parallel, cells 
were treated with free CRISPR/Cas9, liposome-CRISPR/
Cas9 chimeras, liposome-CRISPR/Cas9 chimeras (with 
protamine and calf thymus), A10-liposome-CRISPR/Cas9 
chimeras or A10-liposome- CRISPR/Cas9 chimeras (with 
protamine and calf thymus). To further verify that silencing 
by liposome- CRISPR/Cas9 chimeras is dependent on 
PSMA, LNCap or PC-3 cells were incubated with 2 nM 
DHT for 48 h before the addition of chimeras. Cells were 
collected on day 5 for analysis. Gene knowkdown was 
assessed by RT-PCR of mRNA (50 ng) from cells treated 
with the various CRISPR/Cas9 or chimeras using the 
One-Step RT-PCR Kit (Tiangen, Beijing). All reactions 
were done in a 50-mL volume in triplicate. PCR 
parameters were as follows: 50°C for 30 min, 5 min of Taq 
activation at 95°C, followed by 45 cycles of 95°C × 30 s, 
57°C × 30 s, 72°C × 30 s. Standard curves were generated, 
and the relative amount of target gene mRNA was 
normalized to GAPDH mRNA. Specificity was verified 
by agarose gel electrophoresis.
Cellular uptake study
LNCap cells (2.25 × 105 per well) were seeded in 
6-well plates (Corning Inc.) and allowed to attach and grow 
overnight at 37°C and 5% CO2. Cells were washed with 
PBS 3 times and incubated with various concentrations 
of FAM labeled siRNAs, Lipofectamine-2000-FAM 
labeled CRISPR/Cas9 chimeras, liposome-CRISPR/Cas9 
chimeras, liposome-CRISPR/Cas9 chimeras with protamine 
and calf thymus DNA, or A10-liposome-CRISPR/Cas9 
chimeras with protamine and calf thymus DNA for 4 hr at 
37°C. Treatments were done in triplicate. The cells were 
then washed with PBS 3 times and lysed with 1 mL of 
0.1% Triton-X-100 in PBS. The cells were collected and 
measured for the fluorescence intensity at λem = 562 nm 
and λex = 494 nm by microscopy using a Nikon eclipse 
TE 300 Confocal microscope.
Cell apoptosis assay
The apoptosis of LNCap cells in the presence or 
absence of different chimeras, or without any treatment 
as a blank control, was evaluated by flow cytometry. the 
cells were collected and stained with the Annexin V-FITC 
apoptosis detection kit (KeyGEN, Nanjing, China) 
according to the manufacturer’s instructions, and were 
immediately analyzed via the FACScan flow cytometer 
with 10,000 events collected (Ex: 488 nm; Em: 530 nm).
Cell viability
The viability of LNCap cells in the presence or 
absence of different chimeras, or without any treatment as 
a blank control, was evaluated by 3-[4,5-dimethylthiazol-
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2-yl]-2,5-diphenyl- tetrazoliumbromide (MTT) assay 
over a period of 24 h. LNCap cells were seeded at a 
density of  5,000 cells/well  (200 μL) in 96-well flat-
bottomed microtiter plates over-night. Cells were 
treated with PBS once and incubated with 400 nM free 
siRNA, Lipofectamine-2000, liposomes, liposomes with 
protamine and calf thymus DNA, A10-liposomes, A10-
liposomes with protamine and calf thymus, CRISPR/
Cas9-Lipofectamine-2000 chimeras, liposome-CRISPR/
Cas9 chimeras, liposome-CRISPR/Cas9 chimeras (with 
protamine and calf thymus DNA), or A10-liposome-
CRISPR/Cas9 chimeras (with protamine and calf thymus 
DNA) for 24 h at 37°C, and then washed 3 times with 
PBS. 20 μL of MTT solution (5 mg/mL in PBS) was then 
added to each well and the cells were incubated further 
for 1 hr at 37°C. The media were removed and the cells 
were dissolved in DMSO. Ultraviolet absorbance at 
555 nm was measured in Thermo Electron Corporation 
Multiskan MK3 (Thermo Fisher Scientific Inc.). The data 
are expressed as the percent of viable cells compared to 
untreated control cells.
Animal experiments
Male athymic nude mice (nu/nu) of age 6–8 weeks 
were obtained from BioDure Technology (Beijing, China) 
and maintained in a sterile environment. The First Affiliated 
Hospital of Xi’an Jiaotong University Institutional Animal 
Licensing Committee approved the animal experiments 
undertaken, and the research protocol was in accordance 
with the First Affiliated Hospital of Xi’an Jiaotong 
University institutional guidelines for the Animal Care and 
Use Committee. Mice were inoculated with LNCap cells 
and randomly divided into five groups of nine mice per 
treatment group as follows: no treatment (PBS); treatment 
with free CRISPR/Cas9 (40 μg gRNA + 40 μg Cas9); 
treatment with A10-liposomes-Scrambled CRISPR/Cas9 
chimeras (40 μg A10-liposomes-Scrambled gRNA+ 40 μg 
Cas9); treatment with liposomes-CRISPR/Cas9 chimeras 
(40 μg liposomes-gRNA + 40 μg Cas9); treatment 
with A10-liposomes- CRISPR/Cas9 chimeras (40 μg 
A10-liposomes-gRNA + 40 μg Cas9). Tumors were 
measured every other day with calipers in two dimensions. 
The following formula was used to calculate tumor 
volume: VT = W × L × L × 0.5 (W, the longest dimension; 
L, the shortest dimension). The growth curves are plotted 
as the mean tumor volume ± S.E.M. The animals were 
sacrificed 3 d after the last treatment, and the tumors were 
excised and formalin fithe for immunohistochemistry. 
Slides of serial sections were stained with hematoxylin 
and eosin (H&E).
Cytokine induction assay
Male athymic nude mice (nu/nu) were injected 
i.v. with PBS, free CRISPR/Cas9 (40 μg gRNA + 40 μg 
Cas9), A10-liposomes-Scrambled CRISPR/Cas9 chimeras 
(40 μg A10-liposomes-Scrambled gRNA + 40 μg Cas9), 
liposomes- CRISPR/Cas9 chimeras (40 μg liposomes-
gRNA + 40 μg Cas9), A10-liposomes-CRISPR/Cas9 
chimeras (40 μg A10-liposomes-gRNA + 40 μg Cas9), or 
poly (I:C) (25 µg). Just prior to use, the poly (I:C) stock 
was diluted 1:5 in PBS to provide a 500 µg/mL working 
solution. Two hours after the injections, blood samples 
were collected from the tail artery and incubated at room 
temperature for 0.5 h for coagulation. Serum was obtained 
by centrifuging the clotted blood at 16,000 rpm for 20–40 
min. Cytokine levels were determined using ELISA kits 
for IL-12 and IFN-α (BD Biosciences, San Diego, CA).
Statistical analysis
Statistical analysis was conducted using one-way 
ANOVA, Mann Whitney. P < 0.05 was considered to 
indicate a significant difference. The survival rate was 
analyzed by the chi-square test.
CONCLUSIONS
An aptamer-liposome-CRISPR/Cas9 delivery 
chimera-based approach was designed that combines 
efficient delivery and modified flexibility. The aptamer, 
modified A10 in the chimeras mediates cell type-specific 
binding to human PSMA, a cell-surface receptor expressing 
in prostate cancer cells, whereas, the therapeutic CRISPR/
Cas9 target PLK1. The aptamer-liposome-CRISPR/Cas9 
chimeras are demonstrated not only had a significant 
cell-type specificity in binding and a remarkable gene 
silencing effect in vitro, but also a conspicuous tumor 
regression in vivo, while showed a lower immune response. 
The flexibility of modification on the targeting moiety or 
liposome we described here provides a universal means 
of cell type-specific CRISPR/Cas9 delivery, which is a 
critical goal for the widespread therapeutic applicability of 
CRISPR/Cas9 or other nucleic acid drugs.
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